Does Medicare Cover TRT? A Straight Answer for 2026

The Medicare Picture in 2026

Medicare covers TRT in most situations but the pathway depends on how your treatment is delivered:

• Part B (medical insurance): physician-administered injections, pellet implants, office procedures
• Part D (prescription drugs): self-administered injections, gels, patches, oral testosterone
• Medicare Advantage (Part C): bundles both, sometimes with different cost-sharing

The required documentation is the same across all pathways: two morning total testosterone readings below the reference range plus documented symptoms. The difference is cost structure and how you access the medication.

Documentation Required

Same standards as commercial insurance, but Medicare contractors are typically somewhat stricter on documentation:

1. Two low morning testosterone readings

• Drawn 7-10 a.m.
• Total testosterone below 264 or 300 ng/dL depending on the lab
• Readings on different days, ideally separated by at least 1 week

1. Documented symptoms

• Must be in clinical notes
• Erectile dysfunction, libido loss, fatigue, loss of morning erections, decreased muscle mass — any of these are qualifying when consistent with hypogonadism

1. Ruling out other causes

• TSH and prolactin at minimum
• Often a broader workup as clinically indicated

1. Continued medical necessity

• Periodic labs confirming treatment is working (and not causing problems)
• Annual review by prescribing physician

Part B vs Part D: The Cost Difference

Part B (medical)

Covers physician-administered injections and pellet procedures.

Structure:

• You pay 20% coinsurance after the Part B deductible ($240 in 2026)
• Plus any office visit fee
• Provider bills Medicare directly

Example: quarterly pellet procedure at $800 billed → Medicare pays $640, you pay $160 per procedure = $640/year in coinsurance.

This structure often makes pellets cost-effective for Medicare patients compared to commercially insured patients.

Part D (prescription drugs)

Covers self-administered medications.

Structure:

• Annual deductible (varies by plan, $0-545 in 2026)
• Initial coverage phase: $5-80 copay depending on tier
• Coverage gap ("donut hole"): you pay 25% until hitting catastrophic coverage threshold
• Catastrophic phase: very low copays

Most Part D plans place generic testosterone cypionate on tier 1 or tier 2 (lowest copays).

Brand-name products (Kyzatrex, Jatenzo, Xyosted) are typically tier 3 or 4, with higher copays and prior authorization requirements.

Medicare Advantage Plans

Medicare Advantage (MA) plans bundle hospital, medical, and usually drug coverage under a single private insurer. Coverage for TRT is generally similar to original Medicare, but:

• Out-of-pocket maximums are capped annually (often $4,000-8,000)
• Networks may restrict prescribing physicians
• Some MA plans have richer formularies for testosterone
• Pre-authorization processes vary by plan

If you're on an MA plan, check specifically:

• Is testosterone cypionate on formulary?
• What tier? What copay?
• Any step therapy requirements?
• Does the plan cover needles/syringes?

Real-World Out-of-Pocket Scenarios

Scenario 1: Part B injections

• Quarterly physician-administered injections
• $500/year in coinsurance (20% of billed amount)
• Plus $30-60 office visit each time
• Annual total: $750-900

Scenario 2: Self-administered generic cypionate (Part D)

• Generic testosterone cypionate 200 mg/mL vial (lasts 10-20 weeks at standard doses)
• Part D copay: $5-30 per vial
• Syringes/needles: DME coverage or separate; $10-20/month
• Annual total: $150-400

Scenario 3: Pellets (Part B)

• Three procedures per year
• $160-300 per procedure after 20% coinsurance
• Annual total: $480-900

Scenario 4: Kyzatrex (Part D)

• Brand formulary tier
• No manufacturer copay card for Medicare
• Copay: $50-200/month depending on plan
• Annual total: $600-2,400

For most Medicare patients on TRT, generic self-administered injectable testosterone is the cheapest path.

Common Medicare TRT Obstacles

Prior authorization

Most Part D plans require prior authorization for testosterone. Your physician submits clinical documentation. Initial approval takes 1-2 weeks; denials can be appealed.

Step therapy

Some Part D plans require trying generic first before covering brand. If you're on Kyzatrex and your plan wants you on cypionate first, you may need to switch (or appeal).

Formulary changes

Part D formularies can change annually. A drug covered in 2025 may require prior auth or be moved to a higher tier in 2026. Review your plan's formulary during open enrollment.

Coverage gap

Men in the donut hole may face higher copays for 2-4 months until hitting catastrophic coverage. For TRT, this is usually manageable because the annual cost is modest, but high-cost brand products can accelerate entry into the gap.

Cash-Pay vs Medicare

For Medicare beneficiaries, the cash-pay decision is different than for commercial insurance:

• Online clinics generally charge $99-250/month flat
• Medicare with generic injectable often totals $150-400/year
• Medicare with brand oral can hit $1,500-2,400/year

For Medicare patients wanting generic injectable testosterone, using Medicare is usually cheaper than cash-pay online clinics.

For Medicare patients wanting brand oral or auto-injector options, cash-pay online clinics may or may not be cheaper — depends on the specific drug and your plan's coverage.

Dual Eligibility (Medicare + Medicaid)

If you're dual-eligible:

• Medicare is primary payer
• Medicaid covers Medicare coinsurance and deductibles in most states
• Out-of-pocket can be near-zero
• Exception: Medicaid may not cover brand-name TRT if generic is available

Medigap (Medicare Supplement) Plans

Medigap plans cover the 20% coinsurance Medicare doesn't pay. For TRT specifically:

• Medigap helps substantially for Part B services (injections, pellets)
• Medigap does NOT cover Part D copays (you need separate drug coverage)
• If you take brand-name TRT under Part D, Medigap won't reduce those costs

What to Do if Denied

Medicare denials can be appealed. Common grounds for successful appeals:

1. Additional documentation of symptoms
2. Physician letter emphasizing medical necessity
3. Citing Endocrine Society and AUA guidelines
4. Providing second-opinion documentation
5. Independent-review-organization escalation if all else fails

Appeal process takes 30-90 days depending on stage. Most TRT denials are eventually overturned with persistent physician advocacy.

Bottom Line

Medicare covers TRT for men with documented hypogonadism. The most affordable path for most Medicare beneficiaries is generic self-administered testosterone cypionate through Part D, typically $150-400/year all-in. Physician-administered injections and pellets run higher but may be worth the convenience for some men. Brand-name oral testosterone is meaningfully more expensive on Medicare than on commercial insurance because you can't use manufacturer copay cards. When in doubt, start with labs and a physician conversation; the coverage usually works out if the diagnosis is real.

Sources

1. Centers for Medicare & Medicaid Services. "Local Coverage Determination: Testosterone." 2024.
2. Bhasin S et al. "Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline." J Clin Endocrinol Metab, 2018.
3. Kaiser Family Foundation. "Medicare Prescription Drug Coverage: Plan Design and Cost-Sharing." 2024 review.
4. Medicare.gov official drug coverage information and formulary finder.
5. CMS Medicare Advantage Prescription Drug (MAPD) program documentation.